Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2023

Note 8 - Accounts Payable and Accrued Expenses

At March 31, 2023 and December 31, 2022, accounts payable and accrued expenses consisted of the following ($ in thousands):


	March 31,		December 31,
	2023		2022
Accounts payable	$	14,140	$	11,535
Accrued compensation		1,568		1,195
Research and development		6,593		7,289
Other		319		278
Total accounts payable and accrued expenses	$	22,620	$	20,297